New Flavors in Immunomodulation
Whether to boost the immune system or to tame it, drugs that modulate immune function are becoming an essential part of modern pharmacopoeia. While many of these target molecules that are expressed by immune cells, recent advances in immunometabolism are now opening new classes of modulators that derive from endogenous metabolites.
It is becoming clear that the immune system is involved in many diseases, including conditions that were not traditionally considered infectious, inflammatory, or autoimmune, such as cancer and cardiovascular diseases. In that context, immunomodulation is now a critical part of the pharmaceutic arsenal, either for the potentiation of immune responses, with anti-PD-1 or anti-CTLA-4 as obvious examples, or to limit them, with anti-tumor necrosis factors (TNFs) leading drug sales for the last few years. By and large, research in this area has been focused on blocking immune cytokines and receptors either through antibodies or kinase inhibitors. Now, with two recent studies reporting the use of modified metabolites to suppress immune responses (Kornberg et al., 2018; Mills et al., 2018) , immunometabolism is opening a new front in the quest to modulate immune function.
Indeed, the current approaches have shown extraordinary success, but they have also sometimes been limited by the redundancy of immune activators and inhibitors. For example, immune exhaustion in cancer is mediated by a large variety of soluble and cell-surface molecules, and despite the success of anti-PD-1 as a single agent, many other receptors might need to be blocked simultaneously to improve therapeutic efficiency further and overcome resistance (Sharma et al., 2017) .
In addition to immune mediators, the function of immune cells is also modulated by all core pathways for cellular function, and metabolism has emerged as a critical hub in their activation. This line of inquiry started with the observation that activated T cells rely on aerobic glycolysis to support their proliferation early in a response (Frauwirth et al., 2002) , a phenomenon also observed in cancer cells as the Warburg effect. Beyond proliferation, metabolic shifts have been linked to immune differentiation, for example, in macrophages, where in broad strokes, glycolysis and fatty acid oxidation are induced and necessary for distinct types of responses (Van den Bossche et al., 2017) .
These pathways are critical to provide immune cells with building blocks for proliferation and the production and secretion of effector proteins. Perhaps more surprisingly, the metabolic intermediates of these pathways also appear to play critical roles in shaping the cell's phenotype: succinate, an intermediate in the citric acid cycle, can promote inflammation both in a cell-intrinsic manner and as a soluble signal (Mills and O'Neill, 2014) , while itaconate, a derivative of aconitate produced in the mitochondria, has both anti-microbial and anti-inflammatory effects (Luan and Medzhitov, 2016) As mentioned above, two recent studies are now bridging these basic insights with viable approaches for immunomodulation. First, Snyder and colleagues investigate the mechanism of action of dimethylfumarate (DMF), a derivative of the metabolite fumarate that is currently used as an immunomodulator in psoriasis and multiple sclerosis (Kornberg et al., 2018) . They find that DMF inhibits the enzymatic activity of GAPDH (glyceraldehyde 3-phosphate dehydrogenase, an enzyme that catalyzes the sixth step of glycolysis and has become a staple as a loading and housekeeping control), thereby limiting aerobic glycolysis and inflammation. While this effect may represent a natural feedback loop mediated by fumarate, the modified metabolite appeared to mediate this effect more efficiently because it is more cell permeable and electrophilic. Importantly, this study also demonstrates that targeting of specific metabolic enzymes; here, GAPDH is a viable immunomodulatory strategy. Working with a distinct metabolite, Murphy, O'Neill and colleagues report that 4-octyl itaconate, a cell-permeable derivative of itaconate, is protective in a model of LPS lethality (Mills et al., 2018) . In this case, the effect is mediated by the alkylation of Kelch-like ECH-associated protein 1 (KEAP1), as this modification promotes the stabilization of Nrf2 (also known as NFE2L2, nuclear factor erythroid-derived 2-like 2), that promotes anti-oxidant and anti-inflammatory responses and, in this context, downregulates IL-1b production.
Altogether, these two studies demonstrate that the basic insights accumulated on the role of metabolites in immunomodulation are now opening new therapeutic avenues. The chemical modification of these metabolites and others, to influence either their localization, availability, or ability to modify proteins, is likely to provide a wealth of compounds with immunomodulatory effects. One important caveat of these approaches, however, is that these central metabolic pathways are involved in all cell types and not merely immune cells and could thus have broader side effects, as has been observed to some extent with DMF. More broadly, these
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Cell 173, June 14, 2018 ª 2018 Published by Elsevier Inc. 1553 studies also represent a first step toward immunomodulatory strategies that target the metabolism of immune cells, and while both focus on limiting immune responses, these approaches could also be critical to augment immune function in cancer, where metabolic competition is often thought to limit T cell responses (Chang et al., 2015) , and they are sure to leave immunologists with something to chew on for years to come.
